ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
insight
/
details

Precision Targeting for Cervical Cancer for Optimal Outcomes

NextEdge Admin

05 Feb 2024

2 min 42 sec

Human Papillomavirus (HPV) is a common sexually transmitted infection affecting both men and women. It can lead to various health issues, including genital warts and an increased risk of developing cervical, anal, and throat cancers. Vaccination is a key preventive measure against HPV.

Human Papillomavirus (HPV) infections are often cleared by the immune system, preventing complications. However, persistent HPV infection with oncogenic proteins E6 and E7 can lead to cervical cancer, evading T-cell killing. Immunotherapies target HPV to enhance immune responses. Preventive vaccines are effective, but therapeutic ones targeting HPV-transformed cells show promise in treating pre-cancerous lesions only. In advanced cervical cancer, vaccine efficacy is lower, possibly due to immune resistance. Combining therapies to overcome suppression is crucial.

As a strategy to reverse tumor-mediated immune resistance, Immune checkpoint inhibitors like pembrolizumab show promise, with ongoing trials investigating combinations for improved outcomes in locally advanced cases.

Adoptive cell therapies involve infusing antigen-specific T cells. Studies explore tumor-infiltrating lymphocytes and genetically modified T cells, showing promising responses in metastatic and advanced cervical cancer.

Surface proteins in tumor cells offer targets for antibodies providing an opportunity for development of antibodies and antibody-drug conjugates targeting these antigens. Tisotumab vedotin, targeting tissue factor, demonstrated promising results in pretreated cervical cancer patients.

Radiation therapy is important for locally advanced cervical cancer, involving external beam radiation with cisplatin and brachytherapy. Advancements like image-guided adaptive brachytherapy enhance precision, but global implementation challenges persist.

Efforts in cervical cancer management involve a multidimensional approach, combining vaccines, radiation therapy, adoptive cell therapies, antibody-drug conjugates, and immune checkpoint inhibitors. Challenges include global accessibility and economic feasibility, emphasizing the need for collaborative efforts.